Description
Benefits
- Selectively blocks estrogen receptors in breast tissue
- Commonly used to manage or reduce estrogen-related gynecomastia
- Does not suppress systemic estrogen production
- Preserves estrogen activity in bone and other beneficial tissues
- Supports physique aesthetics without global hormone disruption
- Frequently used in performance and hormone-optimization protocols
Background and History
- Raloxifene was developed as a selective estrogen receptor modulator (SERM)
- SERMs act differently across tissues, blocking estrogen in some while activating it in others
- Raloxifene demonstrates strong antagonism at breast tissue estrogen receptors
- This tissue specificity led to its use in estrogen-sensitive breast conditions
- Over time, it gained attention in performance settings for targeted gynecomastia management
